Mahlon D Johnson

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. Johnson M. PD-L1 expression in meningiomas. J Clin Neurosci. 2018;: pubmed publisher
    ..In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited. ..
  2. Johnson M, O CONNELL M, Pilcher W. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neurooncol. 2011;101:441-8 pubmed publisher
    ..These studies suggest that lopinavir may inhibit meningioma growth, and does so in part by cell cycle arrest. Additional evaluation of lopinavir as a potential adjunct chemotherapy is warranted. ..
  3. request reprint
    Johnson M, Fan X, Bourne P, Walters D. Neuronal differentiation and expression of neural epitopes in pituitary adenomas. J Histochem Cytochem. 2007;55:1265-71 pubmed
    ..These may occur in many forms of adenomas including somatotroph, lactotroph, mixed somatotroph and lactotroph, null cell/gonadotroph cell and, rarely, corticotroph cell adenomas. ..
  4. Johnson M, Reeder J, O CONNELL M. MKP-3 regulates PDGF-BB effects and MAPK activation in meningioma cells. J Clin Neurosci. 2015;22:752-7 pubmed publisher
    ..Reduced MKP-3 may facilitate PDGF-BB autocrine and paracrine mitogenic effects in a subpopulation of higher grade meningiomas by increasing phospho-p44/42 MAPK. ..
  5. Johnson M, Reeder J, O CONNELL M. Bone morphogenetic protein-4 and 7 and receptors regulate vascular endothelial growth factor and receptors in human fetal leptomeninges. Neurosci Lett. 2015;606:225-30 pubmed publisher
    ..The findings show, for the first time, BMP4, BMP7 and receptors are expressed and active in the human fetal leptomeninges. They suggest these BMPs influence vascular development in this tissue by regulating VEGF and its receptors. ..
  6. Johnson M, Vito F, O Connell M. Mesothelin expression in the leptomeninges and meningiomas. J Histochem Cytochem. 2008;56:579-85 pubmed publisher
    ..Future studies may clarify its role in the development of meningiomas, meningeal seeding of gliomas, and metastases to the leptomeninges. ..
  7. Johnson M, Shaw A, O Connell M, Sim F, Moses H. Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas. J Neurooncol. 2011;103:277-85 pubmed publisher
    ..Nonetheless, restoring TGF-β inhibition of meningioma cell proliferation may be an important objective in the design of new chemotherapies for these tumors. ..
  8. Johnson M, O CONNELL M, Facik M, MAURER P, Jahromi B, Pilcher W. Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3. J Neurooncol. 2012;107:121-31 pubmed publisher
  9. Johnson M, O Connell M, WALTER K. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis. BMC Complement Altern Med. 2013;13:303 pubmed publisher
    ..These studies raise the possibility that cucurbitacin I might have value as an adjunct chemotherapy. Additional studies are warranted to evaluate the effects of cucurbitacin I on meningiomas in vivo. ..

More Information

Publications16

  1. Johnson M, Reeder J, O CONNELL M. p38MAPK activation and DUSP10 expression in meningiomas. J Clin Neurosci. 2016;30:110-114 pubmed publisher
    ..PDGF-BB increased DUSP10 in MC2 and MC4 and weakly in MC3. TGFB1 increased phosphorylation of p38MAPK and caspase 3 activation. Thus p38MAPK and DUSP10 likely participate in the pathogenesis of meningiomas. ..
  2. Carson Walter E, Winans B, Whiteman M, Liu Y, Jarvela S, Haapasalo H, et al. Characterization of TEM1/endosialin in human and murine brain tumors. BMC Cancer. 2009;9:417 pubmed publisher
    ..The cellular localization of TEM1/endosialin and its expression profile in primary and metastatic brain tumors support efforts to therapeutically target this protein, potentially via antibody mediated drug delivery strategies. ..
  3. Johnson M. Transforming Growth Factor Beta Family in the Pathogenesis of Meningiomas. World Neurosurg. 2017;104:113-119 pubmed publisher
    ..The TGF-? family may represent new targets for chemotherapy and could include inhibitors of kinases activated by TGF-?. ..
  4. request reprint
    Johnson M, Pace J, Burroughs J. Fourth ventricle rosette-forming glioneuronal tumor. Case report. J Neurosurg. 2006;105:129-31 pubmed
    ..Recognition of, and long-term follow up for, this recently described pathological entity may clarify the nature of this lesion and strategies for its optimal management. ..
  5. Johnson M, O Connell M, Vito F, Pilcher W. Bone morphogenetic protein 4 and its receptors are expressed in the leptomeninges and meningiomas and signal via the Smad pathway. J Neuropathol Exp Neurol. 2009;68:1177-83 pubmed publisher
    ..These findings suggest that BMP-4 and BMPRs may play autocrine/paracrine roles and interact with other transforming growth factor-beta superfamily members in regulating meningioma growth and differentiation. ..
  6. Johnson M, Vito F, Xu H, Xu H. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. Appl Immunohistochem Mol Morphol. 2010;18:250-3 pubmed publisher
    ..Our findings suggest that adenocarcinomas with MUC16 expression may have an increased risk for metastases to pleura/peritoneum but not the leptomeninges or brain. ..
  7. Johnson M, O CONNELL M. Na-K-2Cl cotransporter and aquaporin 1 in arachnoid granulations, meningiomas, and meningiomas invading dura. Hum Pathol. 2013;44:1118-24 pubmed publisher
    ..This was extensive in all subtypes of meningiomas studied. These findings suggest that NKCC1 and AQP1 participate in meningioma biology and invasion. NKCC1 might be targeted by FDA-approved NKCC1 inhibitors. ..